An overview on Vadimezan (DMXAA): The vascular disrupting agent

Tumor vascular infarction: prospects and challenges

(2017) Rana Jahanban-Esfahlan et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Combination of nanotechnology with vascular targeting agents for effective cancer therapy

(2017) Rana Jahanban-Esfahlan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Modulating tumor hypoxia by nanomedicine for effective cancer therapy

(2017) Rana Jahanban-Esfahlan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation

(2017) Khaled Seidi et al.   TUMOR BIOLOGY

RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice

(2017) Rana Jahanban-Esfahlan et al.   Scientific Reports

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

(2016) Tahereh Javaheri et al.   Cell Death & Disease

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

STAT3 regulated ARF expression suppresses prostate cancer metastasis

(2015) Jan Pencik et al.   Nature Communications

Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)

(2015) Liang-Chuan S. Wang et al.   NEOPLASIA

Anticancer Flavonoids Are Mouse-Selective STING Agonists

(2013) Sujeong Kim et al.   ACS Chemical Biology

Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy

(2013) Ane B. Iversen et al.   ACTA ONCOLOGICA

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

(2013) S M Tijono et al.   BRITISH JOURNAL OF CANCER

Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid

(2013) J. Conlon et al.   JOURNAL OF IMMUNOLOGY

Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial

(2012) M. J. McKeage et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08)

(2012) Martin Früh et al.   Clinical Lung Cancer

P2Y12protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation

(2012) S. ZHANG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA)

(2011) Michael B Jameson et al.   Expert Opinion on Drug Metabolism & Toxicology

The Safety and Tolerability of Intravenous ASA404 When Administered in Combination with Docetaxel (60 or 75 mg/m2) in Japanese Patients with Advanced or Recurrent Solid Tumors

(2011) H. Daga et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

(2011) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?

(2011) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY

Disrupting established tumor blood vessels

(2010) Mark J. McKeage et al.   CANCER

Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer

(2010) Toyoaki Hida et al.   CANCER SCIENCE

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

(2010) Dietmar W. Siemann   CANCER TREATMENT REVIEWS

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

(2010) R. Pili et al.   CLINICAL CANCER RESEARCH

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

(2010) Michelle Head et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

(2010) Bruce C Baguley et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy

(2010) Bruce C Baguley et al.   Future Oncology

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

(2009) Mark J. McKeage et al.   LUNG CANCER

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

(2008) M J McKeage et al.   BRITISH JOURNAL OF CANCER

Vascular targeted therapies in oncology

(2008) Dietmar W. Siemann et al.   CELL AND TISSUE RESEARCH

Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients

(2008) J. Li et al.   CLINICAL CANCER RESEARCH